In an endeavor to develop a potent vaccine against cancer, Cuban scientists have performed the second round of the clinical trial of a potential vaccine to prevent prostate cancer.
56 patients, who were administered with the vaccine in two hospitals, showed a notable improvement in their condition, Xinhua has reported Urologist Ranfis Rodriguez saying on Monday.
Rodriguez who led the research team at the Center for Genetic Engineering and Biotechnology (CIGB) in Camaguey, a city 530 km east of Havana has confirmed that his team has noticed a reduction in specific prostate tumour antigens with little or no production of testosterone.
The Heber Provac vaccine is administered in advanced stages of prostate cancer but before the patient receives X-ray or chemotherapy treatment, in order to make hormonal suppression possible, he added.
Another expert, Jesus Junco, said the vaccine is made to control stage 3 and 4 malignant tumours. He also hoped that the vaccine should be as effective as or more effective than standard treatments in the future.
He also added that the researchers will study the vaccine's interaction with other drugs and compare it with standard drugs and treatments used to fight the disease.
As per an official data, every year more than 2,500 men develop prostate cancer in Cuba, most of them aged over 60, and 60 percent of the cases are fatal.
--with inputs from IANS
|
|
Comments:
